Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00942331 Phase III Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Completed USA 1
NCT01108055 Phase II Paclitaxel + Pazopanib Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer Completed USA 0
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT01215136 Phase II Everolimus Paclitaxel First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Terminated USA 0
NCT01326871 Phase Ib/II ALT-801 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Completed USA 0
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting USA 0
NCT01780545 Phase II Apatorsen Docetaxel Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Completed USA 0
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed USA 0
NCT02091999 Phase I Enfortumab vedotin-ejfv A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 Completed USA | CAN 0
NCT02108652 Phase II Atezolizumab A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN 0
NCT02122172 Phase II Afatinib Afatinib in Advanced Refractory Urothelial Cancer Terminated USA 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02236195 Phase II Mocetinostat Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes Completed USA 0
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Completed USA | ROU | POL | ITA | BGR 0
NCT02256436 Phase III Pembrolizumab A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) Completed 0
NCT02300610 Phase I Cisplatin + Gemcitabine Enzalutamide Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Completed USA 0
NCT02302807 Phase III Paclitaxel Vinorelbine Atezolizumab Docetaxel A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed USA | TUR | SWE | SVN | ROU | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS 6
NCT02334527 Phase II Palbociclib Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy Terminated USA 0
NCT02335424 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) Completed 0
NCT02365766 Phase Ib/II Cisplatin Pembrolizumab Gemcitabine Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer Active, not recruiting USA 0
NCT02365818 Phase II CG0070 Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure Completed USA 0
NCT02387996 Phase II Nivolumab A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer Completed USA | SWE | POL | ITA | FIN | ESP | DEU | CZE | BEL | AUS 1
NCT02401542 Phase Ib/II Docetaxel + Vofatamab Vofatamab Docetaxel Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21) Terminated USA | TUR | SWE | ITA | GBR | ESP | CZE 2
NCT02412670 Phase II Carboplatin + Gemcitabine Aldoxorubicin + Cisplatin + Methotrexate + Vincristine Sulfate Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer Completed USA 0
NCT02426125 Phase III Ramucirumab Docetaxel A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Completed USA | TUR | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS 6
NCT02437370 Phase I Pembrolizumab Gemcitabine Docetaxel Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Completed USA 0
NCT02443324 Phase I Pembrolizumab + Ramucirumab A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium Completed USA | GBR | FRA | ESP | DEU 1
NCT02459119 Phase II Regorafenib Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) Completed USA 0
NCT02479178 Phase II BIND-014 A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) Terminated USA 1
NCT02496208 Phase I Ipilimumab Cabozantinib + Nivolumab Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Active, not recruiting USA 0
NCT02500121 Phase II Pembrolizumab Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer Completed USA 0
NCT02516241 Phase III Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer Active, not recruiting USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS 7
NCT02553642 Phase II Nivolumab Ipilimumab Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) Completed USA 0
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02567409 Phase II Cisplatin + Gemcitabine Berzosertib + Cisplatin + Gemcitabine Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer Active, not recruiting USA 0
NCT02581982 Phase II Pembrolizumab Paclitaxel Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer Completed USA 0
NCT02589717 FDA approved Atezolizumab An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy Approved for marketing USA 0
NCT02612194 Phase II Crizotinib LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Terminated USA 0
NCT02619253 Phase Ib/II Pembrolizumab + Vorinostat Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma Completed USA 0
NCT02632409 Phase III Nivolumab A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma Active, not recruiting USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG 9
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Completed USA 0
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Completed USA | NLD | FRA | CAN 0
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Completed USA 0
NCT02807636 Phase III Atezolizumab + Carboplatin + Gemcitabine Carboplatin + Gemcitabine The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy Completed USA | TUR | SVN | ROU | POL | NLD | ITA | ISR | GRC | GBR | FIN | EST | ESP | CZE | CAN | BRA | BEL | AUS 17
NCT02812420 Phase I Durvalumab + Tremelimumab Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy Active, not recruiting USA 0
NCT02853305 Phase III Pembrolizumab Carboplatin + Cisplatin + Gemcitabine Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Completed 0
NCT02872714 Phase II Pemigatinib A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) Completed USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | BEL 1
NCT02897765 Phase I Nivolumab NEO-PV-01 + Poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Completed USA 0
NCT02925533 Phase I Pembrolizumab + Vofatamab Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Terminated USA 0
NCT02989064 Phase I MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers Completed USA | ESP | CAN 0
NCT02989584 Phase Ib/II Atezolizumab + Cisplatin + Gemcitabine A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer Active, not recruiting USA 0
NCT03093922 Phase II Atezolizumab + Cisplatin + Gemcitabine A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer Active, not recruiting USA 0
NCT03132922 Phase I afamitresgene autoleucel MAGE-A4c1032T for Multi-Tumor Active, not recruiting USA | CAN 0
NCT03170960 Phase Ib/II Atezolizumab + Cabozantinib Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting POL | NZL | FRA | ESP | AUS 4
NCT03237780 Phase II Atezolizumab Atezolizumab + Eribulin Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Active, not recruiting USA 0
NCT03272217 Phase II Atezolizumab + Bevacizumab Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer Terminated USA 0
NCT03317496 Phase II Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies Terminated USA | ITA | HUN | GBR | ESP | CZE | CAN | AUS 0
NCT03345134 Phase II BCG solution + Pembrolizumab Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy Not yet recruiting USA 0
NCT03359239 Phase I Atezolizumab + PGV 001 Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer Completed USA 0
NCT03361865 Phase III Epacadostat + Pembrolizumab Pembrolizumab Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) Completed USA | POL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUS 5
NCT03374488 Phase III Epacadostat + Pembrolizumab Pembrolizumab Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma Completed USA | TUR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS 4
NCT03397394 Phase II Rucaparib Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS) Terminated USA | ITA | GBR | FRA | ESP | DEU 0
NCT03410693 Phase II Docetaxel Vinflunine Paclitaxel Rogaratinib Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1) Completed USA | SWE | SVK | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS 8
NCT03425201 Phase Ib/II Cabozantinib + Niraparib Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (NICARAGUA) Completed ESP 0
NCT03451331 Phase II Carboplatin + Gemcitabine + Nivolumab Gemcitabine + Nivolumab + Oxaliplatin Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer Completed USA 0
NCT03459846 Phase II Durvalumab + Olaparib Durvalumab A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU) Active, not recruiting USA | ESP | CAN 4
NCT03472274 Phase II Cisplatin + Doxorubicin + Methotrexate + Vinblastine Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Paclitaxel Durvalumab + Tremelimumab Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (DUTRENEO) Completed ESP 0
NCT03473756 Phase Ib/II Atezolizumab Atezolizumab + Rogaratinib Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) Completed USA | ITA | FRA | ESP | DEU | AUT 2
NCT03502681 Phase I Avelumab + Eribulin A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients Terminated USA 0
NCT03502785 Phase Ib/II Atezolizumab + INO-5401 + INO-9012 INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma Active, not recruiting USA 0
NCT03513952 Phase II Atezolizumab + CYT107 Atezolizumab Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Completed USA 0
NCT03517956 Phase I Copanlisib + Rogaratinib Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO) Completed USA | ESP | DEU | BEL 2
NCT03520231 Phase II Carboplatin + Cisplatin + Denosumab + Gemcitabine Carboplatin + Cisplatin + Gemcitabine Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Completed CAN 0
NCT03557918 Phase II Tremelimumab Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer Completed USA 0
NCT03575013 Phase I Avelumab + Docetaxel A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer Active, not recruiting USA 0
NCT03628716 Phase II Atezolizumab + CV301 CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed USA 0
NCT03666988 Phase I GSK3368715 First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) Terminated USA | ESP | CAN | AUS 0
NCT03674424 Phase II Avelumab + Gemcitabine + Paclitaxel Avelumab + Cisplatin + Doxorubicin + Methotrexate + Vinblastine Avelumab Avelumab + Cisplatin + Gemcitabine Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA) Active, not recruiting FRA | BEL 0
NCT03682068 Phase III Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE) Active, not recruiting USA | TUR | POL | ITA | ISR | HUN | ESP | CZE | CAN | BRA | BGR | AUS | ARG 9
NCT03737123 Phase II Atezolizumab + Carboplatin + Gemcitabine Trial of Atezolizumab Plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Terminated USA 0
NCT03775265 Phase III Atezolizumab + Cisplatin + Mitomycin C Fluorouracil + Mitomycin C Atezolizumab + Gemcitabine + Mitomycin C Gemcitabine + Mitomycin C Atezolizumab + Fluorouracil + Mitomycin C Cisplatin + Mitomycin C Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Active, not recruiting USA 0
NCT03821935 Phase I ABBV-151 ABBV-151 + Budigalimab Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | ISR | FRA | ESP | CAN | BEL | AUS 4
NCT03824691 Phase II Cabozantinib + Durvalumab hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" (ARCADIA) Unknown status ITA 0
NCT03869190 Phase Ib/II Atezolizumab + Tocilizumab Atezolizumab + Niraparib Atezolizumab + Hu5F9-G4 Atezolizumab + Enfortumab vedotin-ejfv Atezolizumab + Linagliptin Atezolizumab + Isatuximab Atezolizumab A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS mUC) Active, not recruiting USA | GRC | GBR | FRA | ESP 2
NCT03898180 Phase III Lenvatinib + Pembrolizumab Pembrolizumab Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) Completed USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS | ARG 5
NCT03915405 Phase I Avelumab + KHK2455 KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer Terminated USA | ESP 0
NCT03935347 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + LN-145 + Pembrolizumab Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy Withdrawn USA 0
NCT03980041 Phase II Nivolumab Eganelisib + Nivolumab Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Completed USA | POL | ITA | FRA | ESP | CZE 1
NCT04004442 Phase II AVB-S6-500 + Avelumab Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (COAXIN) Active, not recruiting USA 0
NCT04064190 Phase II Durvalumab + Vactosertib Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition Not yet recruiting USA 0
NCT04066595 Phase II Cabozantinib Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. (CabUC) Terminated DEU 0
NCT04143711 Phase Ib/II DF1001 DF1001 + Pembrolizumab Study of DF1001 in Patients With Advanced Solid Tumors Recruiting USA | NLD | FRA | DNK | BEL 0
NCT04228042 Phase Ib/II Infigratinib Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer Completed USA 0
NCT04294277 Phase II Pemigatinib Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery (PEGASUS) Terminated ITA 0
NCT04349280 Phase I Bintrafusp alfa A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer Terminated USA | NLD | FRA | ESP | CAN 0
NCT04501094 Phase II Bintrafusp alfa A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma Terminated USA 0
NCT04602078 Phase II Atezolizumab + Cisplatin + Gemcitabine Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma (AUREA) Completed ESP 0
NCT04624399 Phase II Atezolizumab Phase 2 Study of Neoadjuvant Immune Checkpoint Inhibitors in Urothelial Cancer (ABACUS-2) Recruiting GBR 0
NCT04628767 Phase III Durvalumab + Gemcitabine Cisplatin + Doxorubicin + Methotrexate + Pegfilgrastim + Vinblastine Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Pegfilgrastim + Vinblastine Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer Recruiting USA 0
NCT04637594 Phase III Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Active, not recruiting USA 0
NCT04678362 Phase II Avelumab + Talazoparib TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma (TALASUR) Recruiting FRA 0
NCT04701918 Phase II Pembrolizumab Pembrolizumab And Cryoablation In Urothelial Carcinoma Recruiting USA 0
NCT04724018 Phase I Enfortumab vedotin-ejfv + Sacituzumab govitecan-hziy Sacituzumab Govitecan Plus EV in Metastatic UC Active, not recruiting USA 0
NCT04848519 Phase II Pembrolizumab + Propranolol Propranolol Hydrochloride and Pembrolizumab for the Treatment of Recurrent or Metastatic Urothelial Cancer Recruiting USA 0
NCT04871529 Phase II Avelumab + Carboplatin + Gemcitabine Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) Suspended USA 0
NCT04879329 Phase II Disitamab vedotin Disitamab vedotin + Pembrolizumab A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 Recruiting USA | ITA | ISR | GBR | ESP | CAN | BEL | AUS | ARG 2
NCT04925284 Phase I XB002 Nivolumab + XB002 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS 1
NCT04940299 Phase II Ipilimumab + Nivolumab + Tocilizumab Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Active, not recruiting USA 0
NCT04953104 Phase II Nivolumab Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression Recruiting USA 0
NCT04963153 Phase I Enfortumab vedotin-ejfv + Erdafitinib Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Recruiting USA | CAN 0
NCT05077709 Phase II IO102-IO103 + Pembrolizumab IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC Active, not recruiting USA | GBR | ESP 0
NCT05092958 Phase III Avelumab + Cabozantinib Avelumab Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Active, not recruiting USA | CAN 0
NCT05176483 Phase I Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) Recruiting USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS 0
NCT05219435 Phase II Ipilimumab + Nivolumab Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (VEXILLUM) Recruiting ESP 0
NCT05239624 Phase II Enfortumab vedotin-ejfv + Pembrolizumab Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer Recruiting USA 0
NCT05562830 Phase Ib/II VLS-101 A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) Active, not recruiting USA | ISR | ESP | DNK | AUS 2
NCT05656235 Phase II Enfortumab vedotin-ejfv + Pembrolizumab Renal Retention in High Grade Upper Tract Urothelial Cancer Not yet recruiting USA 0
NCT05868265 Phase II Enfortumab vedotin-ejfv A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract Recruiting USA 0
NCT05894447 Phase I Naptumomab estafenatox + Pembrolizumab Obinutuzumab Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers Withdrawn USA 0
NCT05911295 Phase III Disitamab vedotin + Pembrolizumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting USA | ITA | ISR | FRA | ESP | CAN | BRA | AUS | ARG 5
NCT06225596 Phase II Avelumab + Carboplatin + Gemcitabine Avelumab + Cisplatin + Gemcitabine BT8009 BT8009 + Pembrolizumab Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | ARG 5
NCT06356155 Phase II Enfortumab vedotin-ejfv + Pembrolizumab Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer (NEPTUNE) Not yet recruiting USA 0
NCT06630247 Phase I XL495 A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT06660654 Phase II Raludotatug deruxtecan A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) Not yet recruiting USA 0